• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA grants priority review to Astellas’ NDA for gilteritinib pharmaceutical-technology
    June 01, 2018
    The US Food and Drug Administration (FDA) has accepted Astellas Pharma’s new drug application (NDA) for gilteritinib and granted priority review for the product’s use in the treatment of acute myeloid leukaemia (AML).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service